SCHEMBL3409702

SCHEMBL3409702

O=C(COCC1CCCN(S(=O)(=O)c2c(Cl)cc(Cl)cc2Cl)C1)NC1CCC(c2ccccc2)(N2CCCC2)CC1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
POLB P06746 3/20 0.41
GAA P10253 2/20 0.41
ALDH1A1 P00352 7/20 0.39
TDP1 Q9NUW8 2/20 0.39
LMNA P02545 4/20 0.37
RAB9A P51151 2/20 0.37
ACLY P53396 1/20 0.36
NPC1 O15118 1/20 0.36
ATM Q13315 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
PKM P14618 1/20 0.34
SCN1A P35498 1/20 0.34
SCN8A Q9UQD0 1/20 0.34
CCR1 P32246 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3410213 0.88 SMN1; SMN2 (0.42) SMN1; SMN2MEN1KMT2APOLBGAA
SCHEMBL3412777 0.87 NPY1R (0.39) SMN1; SMN2MEN1KMT2APOLBGAA
SCHEMBL3406843 0.86 SMN1; SMN2 (0.38) SMN1; SMN2MEN1KMT2APOLBGAA
SCHEMBL3412330 0.85 SMN1; SMN2 (0.40) SMN1; SMN2MEN1KMT2APOLBGAA
SCHEMBL3412820 0.85 SMN1; SMN2 (0.40) SMN1; SMN2MEN1KMT2APOLBGAA
SCHEMBL493282 0.81 SMN1; SMN2 (0.40) SMN1; SMN2MEN1KMT2APOLBGAA
SCHEMBL3409691 0.81 KMT2A (0.37) SMN1; SMN2MEN1KMT2APOLBGAA
SCHEMBL493196 0.79 ALDH1A1 (0.38) SMN1; SMN2MEN1KMT2APOLBGAA
SCHEMBL3406387 0.79 ALDH1A1 (0.37) SMN1; SMN2MEN1KMT2APOLBGAA
SCHEMBL5122673 0.78 CCR1 (0.45) ACLYCCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257527-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-12-08 EP claimed
US-20090253669-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2009-10-08 US claimed
WO-2009115257-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2009-09-24 WO claimed
EP-2257527-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-12-08 EP disclosed
US-20090253669-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2009-10-08 US disclosed
WO-2009115257-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253669-A1 Substituted Sulfonamide Compounds SULT2A1, STS, SULT1A1 SMN1; SMN2 824/4885MEN1 2751/4885KMT2A 1309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.